Comparison of sulbactam-cefoperazone with carbapenems as empirical monotherapy for febrile neutropenic children with lymphoma and solid tumors

Pediatric Hematology and Oncology

Volumn 28, Issue 4, 2011, Pages 299-310

  Demir, Haci Ahmet ^a   Kutluk, Tezer ^a   Ceyhan, Mehmet ^a   Yaci Küpeli, Begül ^a   Akyüz, Canan ^a   Cengiz, Bülent ^a   Varan, Ali ^a   Kara, Ate ^a   Yalçin, Bilgehan ^a   Seçmeer, Gülten ^a   Büyükpamukçu, Münevver ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

carbapenem; children; febrile neutropenia; lymphoma; solid tumor; sulbactamcefoperazone

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; C REACTIVE PROTEIN; CARBAPENEM DERIVATIVE; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; SULPERAZON; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CANCER PATIENT; CANDIDA PARAPSILOSIS; CANDIDIASIS; CAUSE OF DEATH; CHILD; CHILDHOOD DISEASE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; ENTEROCOCCUS FAECALIS; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAM POSITIVE INFECTION; HODGKIN DISEASE; HUMAN; HYPOTENSION; INFANT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MUCOSA INFLAMMATION; NEUROBLASTOMA; NEUROECTODERM TUMOR; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PERIANAL ABSCESS; PNEUMONIA; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RECURRENT FEVER; REPEAT PROCEDURE; RHABDOMYOSARCOMA; SCHOOL CHILD; SOLID TUMOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INTERMEDIUS; STREPTOCOCCUS ORALIS; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; CARBAPENEMS; CEFOPERAZONE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LYMPHOMA; MALE; NEUTROPENIA; SARCOMA; SULBACTAM;

EID: 79955565487     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.552937     Document Type: Article

References (44)

1. Wicki S, Keisker A, Aebi C, et al. Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy. Pediatr Blood Cancer. 2008;51:778-783.
2. Gurney JG, BondyML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 5th ed. Philadlephia: LippincottWilliams & Wilkins; 2006:1-13.
3. Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents. 2000;16:107-111.
4. Link H Böhme A Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Hematol. 2003: 82(Suppl 2) S105-S117. (Pubitemid 37265297)
5. Ahmed N, El-Mahallawy HA, Ahmed IA, et al. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatr Blood Cancer. 2007;49:786-792. (Pubitemid 47519513)
6. Quezada G, Sunderland T,Chan KW, et al.Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children wih cancer. Pediatr Blood Cancer. 2007;48:273-277. (Pubitemid 46238516)
7. Ammann RA Hirt A Lüthy AR Aebi C. Predicting bacteremia in children with fever and chemoyherapy-induced neutropenia; Pediatr Infect Dis J. 2004: 23; 61-67 (Pubitemid 38176764)
8. Paganini HR, Aguirre C, Puppa G, et al. A prospective,multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer. 2007;109:2572-2579. (Pubitemid 46906478)
9. Santolaya ME, Alvarez AM, Aviles CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794-798. (Pubitemid 47329849)
10. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958-7966. (Pubitemid 46657396)
11. Hartel C,DeusterM, Lehrnbacher T, SchultzC.Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49:767-773. (Pubitemid 47519510)
12. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421. (Pubitemid 32642195)
13. Santolaya ME Alvarez AM Aviĺes CL et al., Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia; Clin Infect Dis, 2002; 35; 678-683 (Pubitemid 35024727)
14. SantolayaME Alvarez AM Aviĺes CL t al.; Early hospital discharge followed by outpatientmanagement versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection; J Clin Oncol; 2004: 22; 3784-3789 (Pubitemid 41095219)
15. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177-186. (Pubitemid 43361800)
16. Aparicio J, Oltra A, Llorca C, et al. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer. 1996;32:1739-1743. (Pubitemid 26306886)
17. Kebudi R Görgün O Ayan I et al.; Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors; Med Pediatr Oncol; 2001; 36; 434-441 (Pubitemid 32240457)
18. Freifeld AG,Walsh T,Marshall D, et al.Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165-176.
19. O¢guz A, Karadeniz C, Citak EC, et al. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patientswith solid tumors. Pediatr HematolOncol. 2006;23:245-253. (Pubitemid 43361806)
20. Kutluk T Kurne O Akyüz C et al; Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer; 2004; 42; 284-286 (Pubitemid 38235082)
21. Ariffin H, Ai CL, Lee CL, Abdullah WA. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health. 2006;42:781-784. (Pubitemid 44690824)
22. Müller J,GaramiM, Constantin T, et al.Meropenem in the treatment of febrile neutropenic children; Pediatr Hematol Oncol; 2005; 22; 277-284 (Pubitemid 40770478)
23. Chastagner P, Plouvier E, Eyer D, et al. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer. Med Pediatr Oncol. 2000;34:306-308. (Pubitemid 30176620)
24. HamidahA, Lim YS, Zulkifli SZ, et al. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. SingaporeMed J. 2007;48:615-619. (Pubitemid 351396789)
25. Aksoylar S Cetingül N Kantar M et al., Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children; Pediatr Hematol Oncol; 2004; 21; 115-123 (Pubitemid 38313727)
26. Le Guyader N, Auvrignon A, Vu-Thien H, et al. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer. 2004;12:720-724. (Pubitemid 39362651)
27. Fass RJ, Gregory WW, D'Amato RF, et al. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob Agents Chemother 1990;34:2256-2259. (Pubitemid 20373867)
28. Neu HC, Fu KP, Aswapokee N, et al. Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother 1979;16:150-157. (Pubitemid 9237585)
29. Jones RN, Barry AL. Antimicrobial activity and other in vitro properties of cefoperazone A, the principalmetabolite of cefoperazone sodium. Antimicrob Agents Chemother. 1983;24:293-296. (Pubitemid 13029343)
30. Williams JD. Beta-lactamases and beta-lactamase inhibitors. Int J Antimicrob Agents. 1999;1(Suppl 1):S3-S7.
31. Bodey G, Abi-Said D, Rolston K, et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 1996;15:625-634. (Pubitemid 26326751)
32. Chandrasekar PH. Safety and efficacy of cefoperazone plus sulbactam versus ceftazidime in the empiric treatment of febrile neutropenia. J PharmTechnol. 1998;14:63-69. (Pubitemid 28175910)
33. Winston DJ, Bartoni K, Bruckner DA, et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis. 1998;26:576-583. (Pubitemid 28155002)
34. Horiuchi A,Hasegawa H, Kageyama T, et al. Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. DiagnMicrobiol Infect Dis. 1989;12:215S-219S. (Pubitemid 20005464)
35. Görgün Ö, Ayan I, Kebudi R, et al. Solid t ümörl ü febril nötropenik hastalarda Sefoperazon + sulbaktam ile Seftazidimin kars̈cedil;ilas̈cedil;tirilmasi. THOD; 1999; 9; 151-158
36. El-Haddad AMA. Comparison of sulbactam-cefoperazone versus piperacilline plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. Curr Ther. Res. 1995;56:1094-1099.
37. Lehrnbecher T, Foster C, Vazquez N, et al.Therapy-induced alterations in host defence in children receiving therapy for cancer. J Pediatr Hematol Oncol. 1997;19:399-417. (Pubitemid 28076484)
38. Viscoli C, Castagnola E, CaniggiaM, et al. Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology. 1988;55:489-500.
39. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176-189. (Pubitemid 43160156)
40. Mendes AV Sapolnik R Mendonça N., New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients; J Pediatr (Rio J); 2007; 83(Suppl 2); S54-S63 (Pubitemid 46920392)
41. Gaur AH, Flynn PM, Shenep JL. Optimum management of pediatric patients with fever and neutropenia. Indian J Pediatr. 2004;71:825-835. (Pubitemid 39350135)
42. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751. (Pubitemid 34194843)
43. Hopkins HA, Sinkowitz-Cochran RL, Rudin BA, et al. Vancomycin use in pediatric hematologyoncology patients. Infect Control Hosp Epidemiol. 2000;21:48-50.
44. Düzova A Kutluk T Kanra G et al.Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors; Turk J Pediatr; 2001: 43, 105-109 (Pubitemid 32537265)